Riskpilot← Back to searchSign inGet full accessFormula Swiss Medical ApS
APSActiveCVR 42242306Vesterbrogade 208Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2021— employees
Revenue 2024
DKK 0
EBITDA margin
—
Equity ratio
-5356.2%
Financial strength
Net profit 2024
DKK 159K
+828% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK 0 | — |
| Net profit | DKK 159K | +828% |
| Total assets | DKK 2K | -98% |
| Equity | DKK -133K | +54% |
| Employees | — | — |
Legal name
Formula Swiss Medical ApS
CVR number
42242306
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
18. marts 2021
Share capital
DKK 40.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at importere kvalitets hamp under forsøgsordningen i Danmark til kliniske forsøg på hospitaler samt via praktiserende læger.
Address
Vesterbrogade 208
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | -69 | -241 | -22 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 |
| EBITDA | -69 | -241 | -22 | 0 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -69 | -241 | -22 | 0 |
| Net financials | -0 | -1 | -0 | 159 |
| Profit before tax | -69 | -241 | -22 | 159 |
| Tax | -0 | -0 | -0 | -0 |
| Net profit | -69 | -241 | -22 | 159 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 39 | 161 | 138 | 2 |
| Equity | -29 | -271 | -292 | -133 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 68 | 432 | 430 | 136 |
| Total debt | 68 | 432 | 430 | 136 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20212024
Equity ratio
-5356.2%
This company
38.2%
Market median
-14121% vs market
20212024
Return on equity
15893800.0%
This company
18.4%
Market median
+86379248% vs market
20212024
Net profit margin
15893800.0%
This company
8.1%
Market median
+196219653% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-03-18 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
RR Management | Management | 2024 |
DF Founder | Founder | 2021 |
| Former (1) | ||
HK Management | Management | 2021 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
| Chairman | 2021 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2024 | |
| Individual | 20–24.99% | 20–24.99% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Formula Swiss Medical ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Robin Roy Krigslund-Hansen | Management | 0 companies |
| Heinz Kvottrup Lorentzen | Management | 0 companies |
| Dennis Farcinsen Leth | Founder | 0 companies |
| Peter Møller Lassen | Chairman | 0 companies |